Cerner Enviza, an independent research agency, is collaborating with a sponsoring pharmaceutical company, with the assistance of Melanoma UK and Global Perspectives, to conduct an online research to collect the opinion of patients with stage 2, 3 or 4 melanoma about the potential benefits and risks related to melanoma treatments.

The data from this research aims provide the medical community with a better understanding of what treatment characteristics are most important to patients. 

Patient participation in this survey is critical for understanding the preferences of patients affected by melanoma.

If you would like to participate please contact Global Patients (the agency in charge of recruitment) directly stating your wish to participate at [email protected] Global Patients will then contact you for answering a few preliminary questions to check your eligibility for the research.

If you are eligible, you will receive a link to the online research which will take approximately 30 minutes to complete and as a token of our appreciation you will receive £50. 

We really do appreciate your continued support in the fight against melanoma

Gill & Di